Exiqon to Divest CLIA Lab; Seeks Partners | GenomeWeb

NEW YORK (GenomeWeb News) – Exiqon today said that it will divest its California-based CLIA lab, Oncotech, in an effort to "gain operational and infrastructural efficiencies and to free up human financial resources."

The Vedbaek, Denmark-based molecular diagnostics firm also said that as a consequence of the divestiture it would seek partners to co-develop and commercialize its miRNA-based diagnostic products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."